Function of Lymphocyte-activation gene 3 (LAG-3) In Immunity


淋巴细胞激活基因-3在免疫中的作用

报告人: 黄新平

组 员:谢思 李龙图 徐扬


2019.01.12

Tumor microenvironment and immune checkpoints: LAG-3



Ligand interaction and structural similarities between LAG3 and CD4





Antigen Presenting Cell TCR Signal MHC class II Melanoma Cell KIEELE LSECtin Glycosylation Galectin-3 T Cell Melanoma Stromal Cell Cell

(Triebel et al.,1990)

(Andrews et al.,2017)

Understanding functions of LAG-3 by Uniprot

```
Protein Lymphocyte activation gene 3 protein
      Gene LAG3
  Organism Homo sapiens (Human)
     Status Reviewed - Annotation score: •••• - Experimental evidence at protein level
Function<sup>1</sup>
Involved in lymphocyte activation. Binds to HLA class-II antigens.
GO - Molecular function i

    antigen binding Source: ProtInc -

    transmembrane signaling receptor activity

        ✓ Source: Ensemble

  View the complete GO annotation on QuickGO ...
GO - Biological processi

    antigen processing and presentation of exogenous peptide antigen via MHC class II  Source: Reactome


    cell surface receptor signaling pathway
    ✓ Source: Ensemble

    negative regulation of interleukin-2 biosynthetic process
    ♥ Source: Ensemble


    negative regulation of T cell activation
    ✔ Source: Ensemble

    positive regulation of natural killer cell mediated cytotoxicity
    Source: Ensembler
```

Interactions between lag-3 and other proteins in immunity





LAG3 is conserved in Mammalia (Blastp)



Homo sapiens
Pan paniscus
Gorilla gorilla gorilla
Pan troglodytes
Pongo abelii
Rhinopithecus bieti
Chlorocebus sabaeus
Elephantulus edwardii

LAG3 and CD4 have some homology (MEGA)





Please cite this article in press as: Wang et al., Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3, Cell (2019), https://doi.org/10.1016/j.cell.2018.11.010

Article

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Jun Wang,¹ Miguel F. Sanmamed,¹ Ila Datar,² Tina Tianjiao Su,¹ Lan Ji,¹ Jingwei Sun,¹ Ling Chen,³ Yusheng Chen,⁴ Gefeng Zhu,¹ Weiwei Yin,⁵ Linghua Zheng,¹ Ting Zhou,¹ Ti Badri,¹ Sheng Yao,¹ Shu Zhu,¹ Agedi Boto,^{1,2} Mario Sznol,⁶ Ignacio Melero,⁷ Dario A.A. Vignali,^{8,9} Kurt Schalper,² and Lieping Chen^{1,3,6,10,*}

¹Department of Immunobiology, Yale University, New Haven, CT 06511, USA

²Department of Pathology, Yale University, New Haven, CT 06510, USA

³Immunotherapy Institute, Fujian Medical University, Fuzhou, Fujian 350108, China

⁴Provincial Clinical Medical College, Fujian Medical University, Fuzhou, Fujian 350108, China

⁵Key Laboratory for Biomedical Engineering of Ministry of Education, College of Biomedical Engineering and Instrument Science,

Zhejiang University, Hangzhou 310027, China

Department of Medicine (Medical Oncology), Yale University, New Haven, CT 06510, USA

⁷Department of Immunology and Immunotherapy, University of Navarra, Pampiona 31008, Spain


⁸Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15213, USA

⁹Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA


¹⁰Lead Contact

*Correspondence: lieping.chen@yale.edu https://doi.org/10.1016/j.cell.2018.11.010


LAG-3 interact with FGL-1 mainly by D1D2 domain




D1D2 domains are IG domain and Ig-like domain




We try to predict the structure of LAG3 by homology modeling







We get the structure of LAG-3 via SWISS-MODEL




CD4 serve as a template of structure prediction




The predicted model of LAG-3






This prediction is reliable via procheck





The LAG-3 contains parallel β -sheet




Susan B.FowlerJaneClarke structure (2001)

Leucine-rich repeat (LRR) is another feature of LAG-3





FGL1-LAG-3 is an important immune evasion mechanism and have implications for the design of cancer immunotherapy



Thank You